As TG Therapeutics Inc.'s phase IIb win in the follicular lymphoma (FL) cohort of the Unity-NHL pivotal experiment testing umbralisib charmed Wall Street, CEO Michael Weiss told investors that the New York-based company is "completely committed to getting our marginal zone lymphoma [MZL] filing in on time and getting to the market" soon. Nobody's forgetting about the opportunity in chronic lymphocytic leukemia (CLL), either.